

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Andrew R. Marks  
U.S. Serial No.: 10/809,089  
Confirmation No.: 7653  
Filing Date: March 25, 2004  
Group Art Unit: 1609  
Examiner: PACKARD, BENJAMIN J  
Title: **NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE  
DRUGS THAT TARGET THE LEAK IN THE RYANODINE  
RECEPTOR (RYR2) AND USES THEREOF**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT WITH AMENDMENT**

This paper is filed in reply to the Office Action of July 10, 2007. The reply was originally due on August 10, 2007. Applicants request three-month extension, which makes the reply due on November 10 2007. Therefore, this paper is being filed timely. The Commissioner is authorized to charge any fees that might be due to Deposit Account No. 08-0219.

In response to the Restriction Requirement, Applicants elect, without traverse, the claims of Group II, and the species of compound S36 as encompassed by chemical formula (g).

**Amendment to the Claims** begins on page 2.

**Remarks** begin on page 10.